Paper Details

  1. Home
  2. Paper Details

48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort.

Author: Cabello-UbedaAlfonso, GutiérrezÁngela, GórgolasMiguel, Hernández SeguradoMarta, Martín CarboneroLuz, MenaÁlvaro, PalmierEsmeralda, PintoAdriana, PulidoFederico, SanzJesús, TejerinaFrancisco, TorralbaMiguel, VergasJorge, VázquezPilar, de QuirósJuan Carlos López Bernardo

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

In a real-life multicenter cohort of 135 ART-naïve patients living with HIV, treatment initiation with DTG + 3TC showed high effectiveness (85.2% at week 48) and favorable safety results, comparable to those of randomized clinical trials. Starting treatment before receiving baseline drug resistance testing results did not impact the regimen's effectiveness.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The main international guidelines indicate DTG/3TC therapy as one of the preferred regimens for people living with HIV (PLWH), due to its observed efficacy in randomized clinical trials. However, information in real-life cohorts is relatively scarce for first-line use. METHODS: A retros...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678299/

データ提供：米国国立医学図書館（NLM）

Dolutegravir + Lamivudine: A Camel's Journey Through the World of HIV Treatment

HIV treatment has evolved significantly over the years, offering patients a more manageable and hopeful future. This research focuses on the effectiveness and safety of a specific combination therapy, dolutegravir (DTG) + lamivudine (3TC), for people living with HIV (PLWH) who have not been previously treated with antiretroviral therapy. It's like exploring a new path across the desert of HIV treatment, seeking to find an optimal combination of medications for optimal results.

A Promising Oasis: Dolutegravir + Lamivudine Shows Strong Results

The study found that DTG + 3TC was highly effective in suppressing HIV viral load in the majority of patients, even those who had previously unknown drug resistance mutations. This is like discovering a resilient oasis in the desert, offering a safe haven even amidst challenging conditions. The study also showed that starting treatment before knowing the results of baseline drug resistance testing did not impact the effectiveness of the regimen. This is like having a trusted guide who can lead you through the desert, regardless of unexpected obstacles.

Navigating the Path to Health: A Camel's Perspective

This research highlights the importance of finding the right treatment approach for each individual living with HIV. It emphasizes the need for personalized care and careful monitoring to ensure optimal outcomes. Just as a camel caravan carefully navigates the desert landscape, we must thoughtfully consider the needs of each patient and seek the most effective treatment options to optimize their health and well-being.

Dr. Camel's Conclusion

This research provides valuable insights into the effectiveness and safety of DTG + 3TC combination therapy for ART-naïve PLWH. It's like finding a new and improved path across the desert of HIV treatment, offering a beacon of hope for patients seeking a brighter future. As researchers, we must continue to explore and develop innovative treatment strategies to combat HIV and ensure the well-being of all those affected by this challenging disease.

Date :
  1. Date Completed 2022-11-23
  2. Date Revised 2023-01-05
Further Info :

Pubmed ID

36409695

DOI: Digital Object Identifier

PMC9678299

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.